<p>LifeMD（纳斯达克代码：LFMD - 获取免费报告）在周六发布给投资者的研究报告中，被华尔街 Zen 从 “持有” 评级下调至 “卖出” 评级。</p>
<ul>
<li>新任首席执行官能否振兴这只挣扎中的远程医疗股票？</li>
</ul>
<p>其他几位股票研究分析师也最近对该公司发表了评论。Cantor Fitzgerald 在 3 月 10 日的报告中重申了对 LifeMD 股票的 “增持” 评级。BTIG Research 在 5 月 4 日的报告中重申了 “买入” 评级，并将 LifeMD 股票的目标价设定为 10.00 美元。HC Wainwright 在 3 月 11 日的报告中将 LifeMD 的目标价从 9.00 美元上调至 10.00 美元，并给予该股票 “买入” 评级。Mizuho 在 3 月 16 日的报告中将 LifeMD 的评级从 “中性” 上调至 “跑赢大盘”，并将该股票的目标价从 6.00 美元上调至 8.00 美元。最后，Weiss Ratings 在周四的报告中将 LifeMD 的评级从 “卖出（e+）” 上调至 “卖出（d）”。七位投资分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 9.14 美元。</p>
<p><strong>查看我们关于 LifeMD 的最新股票报告</strong></p>
<h2>LifeMD 股票上涨 6.5%</h2>
<ul>
<li>Hims &amp; Hers Health 因推出通用 GLP-1 计划而飙升</li>
</ul>
<p>纳斯达克 LFMD 周五开盘价为 4.78 美元。该公司的市值为 2.2753 亿美元，市盈率为 95.62，贝塔值为 2.03。LifeMD 的 52 周最低价为 2.56 美元，52 周最高价为 15.84 美元。该公司的 50 日移动平均价格为 3.87 美元，200 日移动平均价格为 3.93 美元。</p>
<p>LifeMD（纳斯达克代码：LFMD - 获取免费报告）在 5 月 6 日星期三最后发布了季度财报。该公司报告的季度每股收益为（0.20 美元），低于市场共识预期的（0.14 美元）6 美分。该公司季度收入为 5016 万美元，而市场共识预期为 4884 万美元。LifeMD 的净利润率为 2.37%，股本回报率为负 150.88%。平均而言，股票研究分析师预计 LifeMD 在当前年度将发布 0.01 美元的每股收益。</p>
<h2>机构投资者对 LifeMD 的看法</h2>
<ul>
<li>LifeMD 可以凭借其 GLP-1 产品大幅上涨</li>
</ul>
<p>几家机构投资者最近买入和卖出了该股票的股份。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 LifeMD 的持股增加了 4.7%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 49647 股该公司的股票，价值 27 万美元，此前在上个季度又购买了 2235 股。Tower Research Capital LLC TRC 在第二季度将其在 LifeMD 的持股增加了 110.4%。Tower Research Capital LLC TRC 现在拥有 4674 股该公司的股票，价值 6.4 万美元，此前在上个季度又购买了 2452 股。SG Americas Securities LLC 在第四季度将其在 LifeMD 的持股增加了 13.8%。SG Americas Securities LLC 现在拥有 25298 股该公司的股票，价值 8.6 万美元，此前在上个季度又购买了 3061 股。Invesco Ltd.在第四季度将其在 LifeMD 的持股增加了 18.8%。Invesco Ltd.现在拥有 24464 股该公司的股票，价值 8.3 万美元，此前在上个季度又购买了 3870 股。最后，Rhumbline Advisers 在第二季度将其在 LifeMD 的持股增加了 8.7%。Rhumbline Advisers 现在拥有 53589 股该公司的股票，价值 73 万美元，此前在上个季度又购买了 4281 股。机构投资者持有该公司 35.52% 的股票。</p>
<h2>LifeMD 公司简介</h2>
<p>（获取免费报告）</p>
<p>LifeMD（纳斯达克代码：LFMD）是一家总部位于美国的远程医疗公司，提供按需的会员制虚拟医疗服务。通过其数字平台和移动应用，LifeMD 将患者与经过认证的医疗提供者连接，以进行各种急性和慢性疾病的诊断、治疗和持续管理。该公司的核心产品围绕个性化护理计划，支持处方履行、实验室检测和处方配送服务。</p>
<p>LifeMD 的服务组合涵盖多个专业领域，包括男性健康、激素治疗、体重管理和初级护理。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 LifeMD</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 LifeMD 吗？</h2>
<p>在考虑 LifeMD 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 LifeMD 并不在名单上。</p>
<p>虽然 LifeMD 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LFMD

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

美国医疗保健供应商 ETF - iShares

标普医疗保健服务 ETF - SPDR

<p>华尔街禅将 LifeMD（NASDAQ:LFMD）的评级从 “持有” 下调至 “卖出”。尽管如此，几位分析师仍持积极展望，Cantor Fitzgerald 和 BTIG Research 分别给予 “增持” 和 “买入” 评级。LifeMD 的股票开盘价为 4.78 美元，市值为 2.2753 亿美元。该公司报告的季度每股收益为（0.20 美元），未达到预期，但收入为 5016 万美元。机构投资者持有该股票的 35.52%，其 52 周价格区间为 2.56 美元至 15.84 美元。分析师将其评级为 “适度买入”，平均目标价为 9.14 美元</p>

<p>LifeMD (NASDAQ:LFMD - Get Free Report) was downgraded by Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note issued to investors on Saturday.</p>
<div class="lb-trans"><p>LifeMD（纳斯达克代码：LFMD - 获取免费报告）在周六发布给投资者的研究报告中，被华尔街 Zen 从 “持有” 评级下调至 “卖出” 评级。</p>
</div><ul>
<li>Can the New CEO Revive This Struggling Telehealth Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>新任首席执行官能否振兴这只挣扎中的远程医疗股票？</li>
</ul>
</div><p>Several other equities research analysts also recently commented on the company. Cantor Fitzgerald restated an &#34;overweight&#34; rating on shares of LifeMD in a report on Tuesday, March 10th. BTIG Research reiterated a &#34;buy&#34; rating and set a $10.00 price target on shares of LifeMD in a report on Monday, May 4th. HC Wainwright upped their price target on LifeMD from $9.00 to $10.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, March 11th. Mizuho upgraded LifeMD from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and upped their price target for the stock from $6.00 to $8.00 in a report on Monday, March 16th. Finally, Weiss Ratings upgraded LifeMD from a &#34;sell (e+)&#34; rating to a &#34;sell (d)&#34; rating in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $9.14.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也最近对该公司发表了评论。Cantor Fitzgerald 在 3 月 10 日的报告中重申了对 LifeMD 股票的 “增持” 评级。BTIG Research 在 5 月 4 日的报告中重申了 “买入” 评级，并将 LifeMD 股票的目标价设定为 10.00 美元。HC Wainwright 在 3 月 11 日的报告中将 LifeMD 的目标价从 9.00 美元上调至 10.00 美元，并给予该股票 “买入” 评级。Mizuho 在 3 月 16 日的报告中将 LifeMD 的评级从 “中性” 上调至 “跑赢大盘”，并将该股票的目标价从 6.00 美元上调至 8.00 美元。最后，Weiss Ratings 在周四的报告中将 LifeMD 的评级从 “卖出（e+）” 上调至 “卖出（d）”。七位投资分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 9.14 美元。</p>
</div><p><strong>View Our Latest Stock Report on LifeMD</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 LifeMD 的最新股票报告</strong></p>
</div><h2>LifeMD Stock Up 6.5%</h2>
<div class="lb-trans"><h2>LifeMD 股票上涨 6.5%</h2>
</div><ul>
<li>Hims &amp; Hers Health Soars on Generic GLP-1 Rollout Plans</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers Health 因推出通用 GLP-1 计划而飙升</li>
</ul>
</div><p>NASDAQ LFMD opened at $4.78 on Friday. The company has a market cap of $227.53 million, a price-to-earnings ratio of 95.62 and a beta of 2.03. LifeMD has a 52 week low of $2.56 and a 52 week high of $15.84. The business has a 50 day moving average price of $3.87 and a 200-day moving average price of $3.93.</p>
<div class="lb-trans"><p>纳斯达克 LFMD 周五开盘价为 4.78 美元。该公司的市值为 2.2753 亿美元，市盈率为 95.62，贝塔值为 2.03。LifeMD 的 52 周最低价为 2.56 美元，52 周最高价为 15.84 美元。该公司的 50 日移动平均价格为 3.87 美元，200 日移动平均价格为 3.93 美元。</p>
</div><p>LifeMD (NASDAQ:LFMD - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.06). The firm had revenue of $50.16 million for the quarter, compared to the consensus estimate of $48.84 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. On average, equities research analysts anticipate that LifeMD will post 0.01 earnings per share for the current year.</p>
<div class="lb-trans"><p>LifeMD（纳斯达克代码：LFMD - 获取免费报告）在 5 月 6 日星期三最后发布了季度财报。该公司报告的季度每股收益为（0.20 美元），低于市场共识预期的（0.14 美元）6 美分。该公司季度收入为 5016 万美元，而市场共识预期为 4884 万美元。LifeMD 的净利润率为 2.37%，股本回报率为负 150.88%。平均而言，股票研究分析师预计 LifeMD 在当前年度将发布 0.01 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On LifeMD</h2>
<div class="lb-trans"><h2>机构投资者对 LifeMD 的看法</h2>
</div><ul>
<li>LifeMD Can Surge on Its GLP-1 Offerings</li>
</ul>
<div class="lb-trans"><ul>
<li>LifeMD 可以凭借其 GLP-1 产品大幅上涨</li>
</ul>
</div><p>Several institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in LifeMD by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company's stock worth $270,000 after buying an additional 2,235 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company's stock worth $64,000 after buying an additional 2,452 shares in the last quarter. SG Americas Securities LLC boosted its position in LifeMD by 13.8% in the fourth quarter. SG Americas Securities LLC now owns 25,298 shares of the company's stock worth $86,000 after purchasing an additional 3,061 shares during the last quarter. Invesco Ltd. boosted its position in LifeMD by 18.8% in the fourth quarter. Invesco Ltd. now owns 24,464 shares of the company's stock worth $83,000 after purchasing an additional 3,870 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in LifeMD by 8.7% in the second quarter. Rhumbline Advisers now owns 53,589 shares of the company's stock worth $730,000 after purchasing an additional 4,281 shares during the last quarter. Institutional investors own 35.52% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近买入和卖出了该股票的股份。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 LifeMD 的持股增加了 4.7%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 49647 股该公司的股票，价值 27 万美元，此前在上个季度又购买了 2235 股。Tower Research Capital LLC TRC 在第二季度将其在 LifeMD 的持股增加了 110.4%。Tower Research Capital LLC TRC 现在拥有 4674 股该公司的股票，价值 6.4 万美元，此前在上个季度又购买了 2452 股。SG Americas Securities LLC 在第四季度将其在 LifeMD 的持股增加了 13.8%。SG Americas Securities LLC 现在拥有 25298 股该公司的股票，价值 8.6 万美元，此前在上个季度又购买了 3061 股。Invesco Ltd.在第四季度将其在 LifeMD 的持股增加了 18.8%。Invesco Ltd.现在拥有 24464 股该公司的股票，价值 8.3 万美元，此前在上个季度又购买了 3870 股。最后，Rhumbline Advisers 在第二季度将其在 LifeMD 的持股增加了 8.7%。Rhumbline Advisers 现在拥有 53589 股该公司的股票，价值 73 万美元，此前在上个季度又购买了 4281 股。机构投资者持有该公司 35.52% 的股票。</p>
</div><h2>LifeMD Company Profile</h2>
<div class="lb-trans"><h2>LifeMD 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>LifeMD NASDAQ: LFMD is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.</p>
<div class="lb-trans"><p>LifeMD（纳斯达克代码：LFMD）是一家总部位于美国的远程医疗公司，提供按需的会员制虚拟医疗服务。通过其数字平台和移动应用，LifeMD 将患者与经过认证的医疗提供者连接，以进行各种急性和慢性疾病的诊断、治疗和持续管理。该公司的核心产品围绕个性化护理计划，支持处方履行、实验室检测和处方配送服务。</p>
</div><p>LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.</p>
<div class="lb-trans"><p>LifeMD 的服务组合涵盖多个专业领域，包括男性健康、激素治疗、体重管理和初级护理。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than LifeMD</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 LifeMD</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=LFMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in LifeMD Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 LifeMD 吗？</h2>
</div><p>Before you consider LifeMD, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 LifeMD 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 LifeMD 并不在名单上。</p>
</div><p>While LifeMD currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 LifeMD 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

LifeMD (NASDAQ:LFMD) Cut to Sell at Wall Street Zen

Market Beat

LifeMD

Hims & Hers Health

瑞穗金融集团

景顺投资管理

LifeMD Pref Share LFMDP 8.875 Perp 10/15/22

Mizuho Financial Group, Inc.

LifeMD（纳斯达克股票代码：LFMD）在 Wall Street Zen 被降级为卖出评级